Murdock Hunter R.

General Counsel Murdock Hunter R. sold entire 13,514-share position for $1,370,646.68 in 2 transactions

Murdock Hunter R., General Counsel of Axsome Therapeutics, liquidated his entire shareholding of 13,514 shares (-100.0% vs pre-transaction holdings) across 2 separate sales on 2025-06-20 and 2025-06-23 at a blended average price of $101.42. The company is unprofitable, reporting net income of $-59,413,000.00 over its most recent full fiscal year, though revenue growth has been strong at +42.5% year-over-year with quarterly revenue of $121,463,000.00. The stock currently trades at $101.65, -26.2% from its 52-week high of $137.75, and the insider conducted 3 additional sales at this same ticker on 2025-06-16, 2025-06-17, and 2025-06-18 prior to this Form 4 filing. The concentration of sales activity in a narrow timeframe (4 sales within 5 trading days) combined with complete portfolio exit warrants examination of whether operational or capital needs drove the liquidation.

General Counsel Murdock Hunter R. sold all 22,500 shares (22.5K) for $2,276,850.00 across 3 sales at blended average price $101.19.

Murdock Hunter R., General Counsel at Axsome Therapeutics, executed 3 separate sales totaling 22,500 shares for $2,276,850.00 over three trading days (June 16–18, 2025), selling at prices ranging from $100.26 to $102.42. This transaction liquidated his entire shareholding (100% reduction from pre-transaction holdings of 22,500 shares). Notably, Axsome remains unprofitable with net income of $-59,413,000.00 in its most recent full fiscal year, though the company achieved annual revenue growth of 42.5%. The stock trades 25.3% below its 52-week high of $137.75 and has declined 18.5% over the past 90 days. A complete exit by the General Counsel warrants investor attention to any associated corporate developments or changes in management's conviction regarding the company's trajectory.